Newly Identified Regulator in Prostate Cancer Cells Could Serve as Drug Target for Advanced Tumors

Treating advanced prostate cancer typically involves surgery — to reduce levels of testosterone, which fuels the growth of tumors — or giving drugs that blockade the androgen receptor (AR), which responds to testosterone by stimulating cancer-growth genes. While these measures can keep the disease at bay initially, resistance almost always occurs as the androgen receptor … Read more

Prostate Cancer Screening: What You Need to Know

Prostate cancer screening options are available but are not necessarily recommended for all patients. There are positive and negative factors to consider when screening for this cancer, and options should be discussed with a doctor.   Who should be screened for prostate cancer? The U.S. Preventive Services Task Force (USPSTF) recommends that people with prostates … Read more

What is Ureteral Cancer?

Ureteral cancer is a type of cancer that grows in the ureter, or the two thin tubes that connect the kidneys to the bladder. It is uncommon compared with other cancers. What are the ureters? Kidneys make urine by filtering waste and extra water from blood. The urine travels from the kidneys to the bladder … Read more

What Are Radiopharmaceuticals and How Are They Used in Cancer?

Drugs that contain radioactive isotopes — forms of chemical elements that emit radiation — are known as radiopharmaceuticals. Radioisotopes have been used to treat cancer as far back as the 1940s, but the field has really taken off just in the past few years as researchers explore their potential in cancer. How are radiopharmaceuticals used … Read more

Study Pairs Two Forms of Immunotherapy in Patients with Advanced Kidney Cancer

Stymied and disoriented. That’s one way to describe the state of the immune system in some patients with cancer. T cells revved up to attack tumors are turned into an army of loiterers. Cells keenly attuned to signals of infection or disease fail to pick up the faint notes of cancer. A clinical trial led … Read more

Resurrecting an Alternative Treatment for NER-Deficient Bladder Cancer Patients

Discovering new cancer treatment can sometimes be a matter of connecting the dots between new pathways and old drugs. That was the case in a new paper in the TKTK issue of Clinical Cancer Research co-authored by Kent Mouw MD, PhD, co-director of Dana-Farber’s Bladder Cancer Center. Mouw and his team found a promising way … Read more

Newly FDA-Approved Therapy Offers Kidney Cancer Patient a Path Forward

Chuck Stravin carries a white three-ring binder to all of his oncology appointments. Inside are his appointment notes, information about his treatment history, and the latest research and advancements regarding his disease. Nestled alongside these documents also sits a family photo of Stravin, his wife Liz, and their four daughters. Stravin’s family has been instrumental … Read more

Combination Immunotherapy Holds Promise for Patients with Rare Bladder Cancer

A woman recently came to Bradley McGregor, MD, an oncologist at Dana-Farber Cancer Institute, in severe pain with extreme fatigue. Her squamous cell bladder cancer, a rare type for which traditional treatment is generally less effective, had advanced, and it appeared that she had no other options. But timing is everything. McGregor was conducting a … Read more

The Latest Efforts in Precision Oncology for Advanced Prostate Cancer

The management of advanced prostate cancer is rapidly evolving with the application of precision treatments based on genomic testing of tumors’ altered DNA. With recent biomarker-driven drug approvals and increased clinical use of genomic testing, there are a number of opportunities to expand upon this framework. Researchers are calling for increased collaboration and new strategies. … Read more

Biomarker Search Reveals Unexpected Associations in Treatment of Advanced Kidney Cancer

Scientists are gratified when a clinical trial reveals whether one treatment — often an experimental therapy or drug combination — is superior to another. But researchers then often look more deeply into the data, searching for characteristics of tumors associated with a treatment’s effectiveness, or lack of it. In today’s world of precision medicine, identifying … Read more

Researchers Identify New Source of Drug Resistance in Prostate Cancer

For designers of targeted drugs, the biggest bullseye in prostate cancer has been the androgen receptor — a specialized net on prostate cells that snares androgen molecules to spur the cells’ growth. Drugs that block, or inhibit, the receptor can halt the cancer, but not all patients benefit from them, and nearly all those who … Read more

Nobel Prize Research Was a Winning Formula for Patient with Kidney Cancer

Early on an October morning, Shaun Tierney started a promising new treatment for his stage IV kidney cancer. Anxious to tell his longtime oncologist, he texted Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber. What he didn’t expect was that Choueiri would have his own big news: “Kaelin … Nobel … Read more